Abstract
Chimeric antigen receptor-T (CAR-T) cell therapy, as a novel cellular immunotherapy, has dramatically reshaped the landscape of cancer treatment, especially in hematological malignancies. However, relapse is still one of the most troublesome obstacles to achieving broad clinical application. The intrinsic factors and superior adaptability of tumor cells mark a fundamental aspect of relapse. The unique biological function of CAR-T cells governed by their special CAR construction also affects treatment efficacy. Moreover, complex cross-interactions among CAR-T cells, tumor cells, and the tumor microenvironment (TME) profoundly influence clinical outcomes concerning CAR-T cell function and persistence. Therefore, in this review, based on the most recent discoveries, we focus on the challenges of relapse after CAR-T cell therapy in B-cell malignancies from the perspective of tumor cells, CAR-T cells, and the TME. We also discuss the corresponding basic and clinical approaches that may overcome the problem in the future. We aim to provide a comprehensive understanding for scientists and physicians that will help improve research and clinical practice.
概要
嵌合抗原受体T(CAR-T)细胞疗法作为一种新型的细胞免疫疗法,极大地改变了癌症治疗的格局,尤其是在血液系统恶性肿瘤中。然而,CAR-T细胞治疗后复发仍然是影响其广泛应用于临床的主要障碍之一。肿瘤细胞内在特性和较强的适应能力,是复发的一个重要原因。由于特殊CAR结构的存在,CAR-T细胞具有的独特生物学功能同样影响治疗效果。此外,肿瘤微环境中错综复杂的相互作用深刻影响CAR-T细胞功能及临床预后。因此,本综述基于最新发现,从肿瘤细胞、CAR-T细胞和肿瘤微环境角度,关注B细胞恶性肿瘤经CAR-T细胞治疗后复发,讨论未来相应的基础和临床策略,以提供全面的认识,有助于提高研究和临床应用。
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adachi K, Kano Y, Nagai T, et al., 2018. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol, 36(4):346–351. https://doi.org/10.1038/nbt.4086
Ajina A, Maher J, 2018. Strategies to address chimeric antigen receptor tonic signaling. Mol Cancer Ther, 17(9): 1795–1815. https://doi.org/10.1158/1535-7163.MCT-17-1097
Alabanza L, Pegues M, Geldres C, et al., 2017. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol Ther, 25(11):2452–2465. https://doi.org/10.1016/j.ymthe.2017.07.013
Ancos-Pintado R, Bragado-García I, Morales ML, et al., 2022. High-throughput CRISPR screening in hematological neoplasms. Cancers (Basel), 14(15):3612. https://doi.org/10.3390/cancers14153612
Artyomov MN, van den Bossche J, 2020. Immunometabolism in the single-cell era. Cell Metab, 32(5):710–725. https://doi.org/10.1016/j.cmet.2020.09.013
Asnani M, Hayer KE, Naqvi AS, et al., 2020. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia, 34(4):1202–1207. https://doi.org/10.1038/s41375-019-0580-z
Bai ZL, Woodhouse S, Zhao ZR, et al., 2022. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci Adv, 8(23):eabj2820. https://doi.org/10.1126/sciadv.abj2820
Baird JH, Frank MJ, Craig J, et al., 2021. CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. Blood, 137(17):2321–2325. https://doi.org/10.1182/blood.2020009432
Bao C, Gao QL, Li LL, et al., 2021. The application of nanobody in CAR-T therapy. Biomolecules, 11(2):238. https://doi.org/10.3390/biom11020238
Biondi M, Cerina B, Tomasoni C, et al., 2021. Combining the expression of CD33.CAR and CXCR4 to increase CAR-CIK cell homing to bone marrow niche and leukemic stem cell eradication in acute myeloid leukemia. Blood, 138(S1):2791–2791. https://doi.org/10.1182/blood-2021-152394
Boulch M, Cazaux M, Loe-Mie Y, et al., 2021. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Sci Immunol, 6(57):eabd4344. https://doi.org/10.1126/sciimmunol.abd4344
Calderon H, Mamonkin M, Guedan S, 2020. Analysis of CAR-mediated tonic signaling. In: Swiech K, Malmegrim KCR, Picanço-Castro V (Eds.), Chimeric Antigen Receptor T Cells. Springer, New York, p.223–236. https://doi.org/10.1007/978-1-0716-0146-4_17
Cancilla D, Rettig MP, Dipersio JF, 2020. Targeting CXCR4 in AML and ALL. Front Oncol, 10:1672. https://doi.org/10.3389/fonc.2020.01672
Cao Y, Xiao Y, Wang N, et al., 2021. CD19/CD22 chimeric antigen receptor T cell cocktail therapy following autologous transplantation in patients with relapsed/refractory aggressive B cell lymphomas. Transplant Cell Ther, 27(11): 910.e1–910.e11. https://doi.org/10.1016/j.jtct2021.08.012
Cappell KM, Sherry RM, Yang JC, et al., 2020. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J Clin Oncol, 38(32):3805–3815. https://doi.org/10.1200/JCO.20.01467
Chen C, Liu JM, Luo YP, 2020. MicroRNAs in tumor immunity: functional regulation in tumor-associated macrophages. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(1):12–28. https://doi.org/10.1631/jzus.B1900452
Chen GM, Chen CY, Das RK, et al., 2021. Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy. Cancer Discov, 11(9):2186–2199. https://doi.org/10.1158/2159-8290.CD-20-1677
Chen J, López-Moyado IF, Seo H, et al., 2019. NR4A transcription factors limit CAR T cell function in solid tumours. Nature, 567(7749):530–534. https://doi.org/10.1038/s41586-019-0985-x
Chen PH, Lipschitz M, Weirather JL, et al., 2020. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight, 5(12):e134612 https://doi.org/10.1172/jci.insight.134612
Chen YH, Sun C, Landoni E, et al., 2019. Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15. Clin Cancer Res, 25(9):2915–2924. https://doi.org/10.1158/1078-0432.CCR-18-1811
Chong EA, Melenhorst JJ, Lacey SF, et al., 2017. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood, 129(8):1039–1041. https://doi.org/10.1182/blood-2016-09-738245
Colmone A, Amorim M, Pontier AL, et al., 2008. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science, 322(5909): 1861–1865. https://doi.org/10.1126/science.1164390
Dai HR, Wu ZQ, Jia HJ, et al., 2020. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol, 13:30. https://doi.org/10.1186/s13045-020-00856-8
Davenport AJ, Cross RS, Watson KA, et al., 2018. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc Natl Acad Sci USA, 115(9):E2068–E2076. https://doi.org/10.1073/pnas.1716266115
da Vià MC, Dietrich O, Truger M, et al., 2021. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med, 27(4): 616–619. https://doi.org/10.1038/s41591-021-01245-5
Deng Q, Han GC, Puebla-Osorio N, et al., 2020. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med, 26(12):1878–1887. https://doi.org/10.1038/s41591-020-1061-7
Enblad G, Karlsson H, Gammelgård G, et al., 2018. A phase I/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia. Clin Cancer Res, 24(24): 6185–6194. https://doi.org/10.1158/1078-0432.CCR-18-0426
Evans AG, Rothberg PG, Burack WR, et al., 2015. Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. Br J Haematol, 171(2):205–209. https://doi.org/10.1111/bjh.13562
Fan TWM, Bandura LL, Higashi RM, et al., 2005. Metabolomics-edited transcriptomics analysis of Se anticancer action in human lung cancer cells. Metabolomics, 1(4):325–339. https://doi.org/10.1007/s11306-005-0012-0
Fan TWM, Lane AN, Higashi RM, 2016. Stable isotope resolved metabolomics studies in ex vivo tissue slices. Bio Protoc, 6(3):e1730. https://doi.org/10.21769/bioprotoc.1730
Fischer J, Paret C, el Malki K, et al., 2017. CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J Immunother, 40(5):187–195. https://doi.org/10.1097/CJI.0000000000000169
Fraietta JA, Lacey SF, Orlando EJ, et al., 2018a. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med, 24(5):563–571. https://doi.org/10.1038/s41591-018-0010-1
Fraietta JA, Nobles CL, Sammons MA, et al., 2018b. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature, 558(7709):307–312. https://doi.org/10.1038/s41586-018-0178-z
Frank MJ, Hossain NM, Bukhari A, et al., 2021. Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial. J Clin Oncol, 39(27):3034–3043. https://doi.org/10.1200/JCO.21.00377
Fry TJ, Shah NN, Orentas RJ, et al., 2018. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med, 24(1):20–28. https://doi.org/10.1038/nm.4441
Fultang L, Booth S, Yogev O, et al., 2020. Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. Blood, 136(10):1155–1160. https://doi.org/10.1182/blood.2019004500
Gardner R, Wu D, Cherian S, et al., 2016. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood, 127(20):2406–2410. https://doi.org/10.1182/blood-2015-08-665547
Gaudichon J, Jakobczyk H, Debaize L, et al., 2019. Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: reconciling biological concepts and clinical issues. Blood Rev, 36:40–56. https://doi.org/10.1016/j.blre.2019.04.003
Gennert DG, Lynn RC, Granja JM, et al., 2021. Dynamic chromatin regulatory landscape of human CAR T cell exhaustion. Proc Natl Acad Sci USA, 118(30):e2104758118. https://doi.org/10.1073/pnas.2104758118
Ghoneim HE, Fan YP, Moustaki A, et al., 2017. De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation. Cell, 170(1):142–157.e19. https://doi.org/10.1016/j.cell.2017.06.007
Grupp SA, Kalos M, Barrett D, et al., 2013. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med, 368(16):1509–1518. https://doi.org/10.1056/NEJMoa1215134
Guedan S, Posey AD, Shaw C, et al., 2018. Enhancing CAR T cell persistence through ICOS and 4–1BB costimulation. JCI Insight, 3(1):e96976. https://doi.org/10.1172/jci.insight.96976
Guerrouahen BS, Sidahmed H, al Sulaiti A, et al., 2019. Enhancing mesenchymal stromal cell immunomodulation for treating conditions influenced by the immune system. Stem Cells Int, 2019:7219297. https://doi.org/10.1155/2019/7219297
Hamieh M, Dobrin A, Cabriolu A, et al., 2019. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature, 568(7750): 112–116. https://doi.org/10.1038/s41586-019-1054-1
Hanahan D, 2022. Hallmarks of cancer: new dimensions. Cancer Discov, 12(1):31–46. https://doi.org/10.1158/2159-8290.CD-21-1059
Harris DT, Hager MV, Smith SN, et al., 2018. Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains. J Immunol, 200(3): 1088–1100. https://doi.org/10.4049/jimmunol.1700236
Hong MH, Clubb JD, Chen YY, 2020. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell, 38(4):473–488. https://doi.org/10.1016/j.ccell.2020.07.005
Hu TY, Murdaugh R, Nakada D, 2017. Transcriptional and microenvironmental regulation of lineage ambiguity in leukemia. Front Oncol, 7:268. https://doi.org/10.3389/fonc.2017.00268
Hu WH, Zi ZG, Jin YL, et al., 2019. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions. Cancer Immunol Immunother, 68(3):365–377. https://doi.org/10.1007/s00262-018-2281-2
Hu Y, Zhou Y, Zhang M, et al., 2021. CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia. Clin Cancer Res, 27(10):2764–2772. https://doi.org/10.1158/1078-0432.CCR-20-3863
Huang H, Wu HW, Hu YX, 2020. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(1):29–41. https://doi.org/10.1631/jzus.B1900351
Hudecek M, Sommermeyer D, Kosasih PL, et al., 2015. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res, 3(2):125–135. https://doi.org/10.1158/2326-6066.CIR-14-0127
Jacobson C, Locke FL, Ghobadi A, et al., 2021. Long-term (⩾4 year and ⩾5 year) overall survival (OS) by 12- and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients (pts) with refractory large B-cell lymphoma (LBCL). Blood, 138(S1):1764–1764. https://doi.org/10.1182/blood-2021-148078
Jacoby E, Nguyen SM, Fountaine TJ, et al., 2016. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun, 7:12320. https://doi.org/10.1038/ncomms12320
Jain MD, Zhao H, Wang XF, et al., 2021. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood, 137(19):2621–2633. https://doi.org/10.1182/blood.2020007445
Jing XM, Yang FM, Shao CC, et al., 2019. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer, 18:157. https://doi.org/10.1186/s12943-019-1089-9
John S, Pulsipher MA, Moskop A, et al., 2021. Real-world outcomes for pediatric and young adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel: update from the center for international blood and marrow transplant research (CIBMTR) registry. Blood, 138(S1):428. https://doi.org/10.1182/blood-2021-146393
Kadomoto S, Izumi K, Mizokami A, 2021. Macrophage polarity and disease control. Int J Mol Sci, 23(1):144. https://doi.org/10.3390/ijms23010144
Kailayangiri S, Altvater B, Wiebel M, et al., 2020. Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers. Cancers (Basel), 12(5):1075. https://doi.org/10.3390/cancers12051075
Khan O, Giles JR, Mcdonald S, et al., 2019. TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature, 571(7764):211–218. https://doi.org/10.1038/s41586-019-1325-x
Kong WM, Dimitri A, Wang WL, et al., 2021. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. J Clin Invest, 131(16):e145459. https://doi.org/10.1172/JCI145459
Kumar V, Patel SM, Tcyganov E, et al., 2016. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol, 37(3):208–220. https://doi.org/10.1016/j.it.2016.01.004
Langier S, Sade K, Kivity S, 2010. Regulatory T cells: the suppressor arm of the immune system. Autoimmun Rev, 10(2):112–115. https://doi.org/10.1016/j.autrev.2010.08.013
Larson RC, Maus MV, 2021. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer, 21(3):145–161. https://doi.org/10.1038/s41568-020-00323-z
Li N, Hua JL, 2017. Interactions between mesenchymal stem cells and the immune system. Cell Mol Life Sci, 74(13): 2345–2360. https://doi.org/10.1007/s00018-017-2473-5
Li S, Siriwon N, Zhang XY, et al., 2017. Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors. Clin Cancer Res, 23(22):6982–6992. https://doi.org/10.1158/1078-0432.CCR-17-0867
Li YR, Yu YQ, Kramer A, et al., 2022. An ex vivo 3D tumor microenvironment-mimicry culture to study TAM modulation of cancer immunotherapy. Cells, 11(9):1583. https://doi.org/10.3390/cells11091583
Lindo L, Wilkinson LH, Hay KA, 2021. Befriending the hostile tumor microenvironment in CAR T-cell therapy. Front Immunol, 11:618387. https://doi.org/10.3389/fimmu.2020.618387
Long AH, Haso WM, Shern JF, et al., 2015. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med, 21(6): 581–590. https://doi.org/10.1038/nm.3838
Lynn RC, Weber EW, Sotillo E, et al., 2019. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature, 576(7786):293–300. https://doi.org/10.1038/s41586-019-1805-z
Macian F, 2005. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol, 5(6):472–484. https://doi.org/10.1038/nri1632
Majzner RG, Mackall CL, 2018. Tumor antigen escape from CAR T-cell therapy. Cancer Discov, 8(10):1219–1226. https://doi.org/10.1158/2159-8290.CD-18-0442
Maus MV, Haas AR, Beatty GL, et al., 2013. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res, 1(1):26–31. https://doi.org/10.1158/2326-6066.CIR-13-0006
Mcgranahan N, Swanton C, 2017. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell, 168(4): 613–628. https://doi.org/10.1016/j.cell.2017.01.018
Melenhorst JJ, Chen GM, Wang M, et al., 2022. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature, 602(7897):503–509. https://doi.org/10.1038/s41586-021-04390-6
Miao LL, Zhang ZC, Ren ZJ, et al., 2021. Reactions related to CAR-T cell therapy. Front Immunol, 12:663201. https://doi.org/10.3389/fimmu.2021.663201
Muñoz L, Nomdedéu JF, López O, et al., 2001. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica, 86(12):1261–1269.
Orlando EJ, Han X, Tribouley C, et al., 2018. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med, 24(10):1504–1506. https://doi.org/10.1038/s41591-018-0146-z
Pauken KE, Sammons MA, Odorizzi PM, et al., 2016. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science, 354(6316):1160–1165. https://doi.org/10.1126/science.aaf2807
Peled A, Klein S, Beider K, et al., 2018. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies. Cytokine, 109:11–16. https://doi.org/10.1016/j.cyto.2018.02.020
Pinho S, Frenette PS, 2019. Haematopoietic stem cell activity and interactions with the niche. Nat Rev Mol Cell Biol, 20(5):303–320. https://doi.org/10.1038/s41580-019-0103-9
Prasetyanti PR, Medema JP, 2017. Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer, 16:41. https://doi.org/10.1186/s12943-017-0600-4
Prinzing B, Zebley CC, Petersen CT, et al., 2021. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci Transl Med, 13(620):eabh0272. https://doi.org/10.1126/scitranslmed.abh0272
Qi YK, Zhao MF, Hu YX, et al., 2022. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood, 139(23):3376–3386. https://doi.org/10.1182/blood.2021013733
Rafei H, Daher M, Rezvani K, 2021. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Br J Haematol, 193(2):216–230. https://doi.org/10.1111/bjh.17186
Rafiq S, Yeku OO, Jackson HJ, et al., 2018. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol, 36(9):847–856. https://doi.org/10.1038/nbt.4195
Ramakrishna S, Highfill SL, Walsh Z, et al., 2019. Modulation of target antigen density improves CAR T-cell functionality and persistence. Clin Cancer Res, 25(17):5329–5341. https://doi.org/10.1158/1078-0432.CCR-18-3784
Ramos CA, Grover NS, Beaven AW, et al., 2020. Anti-CD30 CAR-T cell therapy in relapsed and refractory hodgkin lymphoma. J Clin Oncol, 38(32):3794–3804. https://doi.org/10.1200/JCO.20.01342
Regmi S, Pathak S, Kim JO, et al., 2019. Mesenchymal stem cell therapy for the treatment of inflammatory diseases: challenges, opportunities, and future perspectives. Eur J Cell Biol, 98(5–8):151041. https://doi.org/10.1016/j.ejcb.2019.04.002
Ren XW, Zhang L, Zhang YY, et al., 2021. Insights gained from single-cell analysis of immune cells in the tumor microenvironment. Annu Rev Immunol, 39:583–609. https://doi.org/10.1146/annurev-immunol-110519-071134
Roselli E, Faramand R, Davila ML, 2021. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes. J Clin Invest, 131(2):e142030. https://doi.org/10.1172/JCI142030
Ruella M, Barrett DM, Kenderian SS, et al., 2016. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest, 126(10):3814–3826. https://doi.org/10.1172/JCI87366
Ruella M, Xu J, Barrett DM, et al., 2018. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med, 24(10): 1499–1503. https://doi.org/10.1038/s41591-018-0201-9
Sadeqi Nezhad M, Abdollahpour-Alitappeh M, Rezaei B, et al., 2021. Induced pluripotent stem cells (iPSCs) provide a potentially unlimited T cell source for CAR-T cell development and off-the-shelf products. Pharm Res, 38(6): 931–945. https://doi.org/10.1007/s11095-021-03067-z
Sakaguchi S, Ono M, Setoguchi R, et al., 2006. Foxp3+CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev, 212(1):8–27. https://doi.org/10.1111/j.0105-2896.2006.00427.x
Salter AI, Rajan A, Kennedy JJ, et al., 2021. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Sci Signal, 14(697):eabe2606. https://doi.org/10.1126/scisignal.abe2606
Savoldo B, Ramos CA, Liu EL, et al., 2011. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest, 121(5):1822–1826. https://doi.org/10.1172/JCI46110
Scarfò I, Ormhøj M, Frigault MJ, et al., 2018. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood, 132(14):1495–1506. https://doi.org/10.1182/blood-2018-04-842708
Scherer F, Kurtz DM, Newman AM, et al., 2016. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med, 8(364):364ra155. https://doi.org/10.1126/scitranslmed.aai8545
Schneider D, Xiong Y, Wu DR, et al., 2017. A tandem CD19/ CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines. J Immunother Cancer, 5(1):42. https://doi.org/10.1186/s40425-017-0246-1
Sen DR, Kaminski J, Barnitz RA, et al., 2016. The epigenetic landscape of T cell exhaustion. Science, 354(6316):1165–1169. https://doi.org/10.1126/science.aae0491
Seo H, Chen J, González-Avalos E, et al., 2019. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc Natl Acad Sci USA, 116(25):12410–12415. https://doi.org/10.1073/pnas.1905675116
Shaffer DR, Savoldo B, Yi ZZ, et al., 2011. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood, 117(16):4304–4314. https://doi.org/10.1182/blood-2010-04-278218
Shah NN, Qin HY, Yates B, et al., 2019. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. Blood Adv, 3(15):2317–2322. https://doi.org/10.1182/bloodadvances.2019000219
Shalabi H, Kraft IL, Wang HW, et al., 2018. Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. Haematologica, 103(5):e215–e218. https://doi.org/10.3324/haematol.2017.183459
Shao M, Teng XY, Guo X, et al., 2022. Inhibition of calcium signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via SOCE-calcineurin-NFAT and glycolysis pathways. Adv Sci (Weinh), 9(9):2103508. https://doi.org/10.1002/advs.202103508
Si XH, Xiao L, Brown CE, et al., 2022. Preclinical evaluation of CAR T cell function: in vitro and in vivo models. Int J Mol Sci, 23(6):3154. https://doi.org/10.3390/ijms23063154
Siddiqi T, Wang XL, Blanchard MS, et al., 2021. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Adv, 5(20):4059–4063. https://doi.org/10.1182/bloodadvances.2020004106
Singh N, Lee YG, Shestova O, et al., 2020. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov, 10(4):552–567. https://doi.org/10.1158/2159-8290.CD-19-0813
Sotillo E, Barrett DM, Black KL, et al., 2015. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov, 5(12):1282–1295. https://doi.org/10.1158/2159-8290.CD-15-1020
Stepanov AV, Markov OV, Chernikov IV, et al., 2018. Autocrine-based selection of ligands for personalized CAR-T therapy of lymphoma. Sci Adv, 4(11):eaau4580. https://doi.org/10.1126/sciadv.aau4580
Sterner RC, Sterner RM, 2021. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J, 11(4):69. https://doi.org/10.1038/s41408-021-00459-7
Sun Y, Su YF, Wang YZ, et al., 2021. CD19 CAR-T cells with membrane-bound IL-15 for B-cell acute lymphoblastic leukemia after failure of CD19 and CD22 CAR-T cells: case report. Front Immunol, 12:728962. https://doi.org/10.3389/fimmu.2021.728962
Tallen G, Ratei R, Mann G, et al., 2010. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol, 28(14):2339–2347. https://doi.org/10.1200/JCO.2009.25.1983
Tan Y, Pan J, Deng BP, et al., 2021. Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL. Cancer Immunol Immunother, 70(7):1979–1993. https://doi.org/10.1007/s00262-020-02829-9
Thankamony AP, Subbalakshmi AR, Jolly MK, et al., 2021. Lineage plasticity in cancer: the tale of a skin-walker. Cancers (Basel), 13(14):3602. https://doi.org/10.3390/cancers13143602
Thoms JAI, Pimanda JE, Heidenreich O, 2021. To switch or not to switch: PU.1 expression is the question. Blood, 138(15):1289–1291. https://doi.org/10.1182/blood.2021012112
Tong C, Zhang Y, Liu Y, et al., 2020. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood, 136(14):1632–1644. https://doi.org/10.1182/blood.2020005278
Tu SF, Zhou X, Guo ZL, et al., 2019. CD19 and CD70 dual-target chimeric antigen receptor T-cell therapy for the treatment of relapsed and refractory primary central nervous system diffuse large B-cell lymphoma. Front Oncol, 9:1350. https://doi.org/10.3389/fonc.2019.01350
van Bruggen JAC, Martens AWJ, Fraietta JA, et al., 2019. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy. Blood, 134(1):44–58. https://doi.org/10.1182/blood.2018885863
Walker AJ, Majzner RG, Zhang L, et al., 2017. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol Ther, 25(9):2189–2201. https://doi.org/10.1016/j.ymthe.2017.06.008
Wang DR, Prager BC, Gimple RC, et al., 2021. CRISPR screening of CAR T cells and cancer stem cells reveals critical dependencies for cell-based therapies. Cancer Discov, 11(5):1192–1211. https://doi.org/10.1158/2159-8290.CD-20-1243
Wang H, Kaur G, Sankin AI, et al., 2019. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol, 12:59. https://doi.org/10.1186/s13045-019-0746-1
Wang JS, Hu YX, Huang H, 2017. Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy. J Leukoc Biol, 102(6):1347–1356. https://doi.org/10.1189/jlb.5RU0817-315R
Wang WL, Fasolino M, Cattau B, et al., 2020. Joint profiling of chromatin accessibility and CAR-T integration site analysis at population and single-cell levels. Proc Natl Acad Sci USA, 117(10):5442–5452. https://doi.org/10.1073/pnas.1919259117
Wang Y, Tong C, Dai HR, et al., 2021. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat Commun, 12:409. https://doi.org/10.1038/s41467-020-20696-x
Weber EW, Parker KR, Sotillo E, et al., 2021. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science, 372(6537):eaba1786. https://doi.org/10.1126/science.aba1786
Webster B, Xiong Y, Hu PR, et al., 2021. Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19+ Raji lymphoma in preclinical models. Mol Ther, 29(9):2691–2706. https://doi.org/10.1016/j.ymthe.2021.05.006
Williams MTS, Yousafzai YM, Elder A, et al., 2016. The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts. Blood, 127(16):1998–2006. https://doi.org/10.1182/blood-2015-08-665034
Wilson WR, Hay MP, 2011. Targeting hypoxia in cancer therapy. Nat Rev Cancer, 11(6):393–410. https://doi.org/10.1038/nrc3064
Xia LZ, Oyang L, Lin JG, et al., 2021. The cancer metabolic reprogramming and immune response. Mol Cancer, 20:28. https://doi.org/10.1186/s12943-021-01316-8
Xu XQ, Gnanaprakasam JNR, Sherman J, et al., 2019. A metabolism toolbox for CAR T therapy. Front Oncol, 9:322. https://doi.org/10.3389/fonc.2019.00322
Yan LE, Zhang HY, Wada M, et al., 2020. Targeting two antigens associated with B-ALL with CD19-CD123 compound CAR T cell therapy. Stem Cell Rev Rep, 16(2): 385–396. https://doi.org/10.1007/s12015-019-09948-6
Yan N, Wang N, Wang GX, et al., 2022. CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation. Cytotherapy, 24(8):841–849. https://doi.org/10.1016/j.jcyt.2022.01.011
Yan X, Chen DY, Wang Y, et al., 2022. Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies. Signal Transduct Target Ther, 7:98. https://doi.org/10.1038/s41392-022-00915-1
Yan ZX, Li L, Wang W, et al., 2019. Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor T cells in refractory B-cell non-Hodgkin’s lymphoma. Clin Cancer Res, 25(23):6995–7003. https://doi.org/10.1158/1078-0432.CCR-19-0101
Yang X, Yu QX, Xu H, et al., 2021. Upregulation of CD22 by chidamide promotes CAR T cells functionality. Sci Rep, 11(1):20637. https://doi.org/10.1038/s41598-021-00227-4
Yang XO, Nurieva R, Martinez GJ, et al., 2008. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity, 29:44–56. https://doi.org/10.1016/j.immuni.2008.05.007
Ying ZT, He T, Wang XP, et al., 2019. Parallel comparison of 4–1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin’s lymphoma. Mol Ther Oncolytics, 15:60–68. https://doi.org/10.1016/j.omto.2019.08.002
You LS, Han QM, Zhu L, et al., 2020. Decitabine-mediated epigenetic reprograming enhances anti-leukemia efficacy of CD123-targeted chimeric antigen receptor T-cells. Front Immunol, 11:1787. https://doi.org/10.3389/fimmu.2020.01787
Yu H, Sotillo E, Harrington C, et al., 2017. Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. Am J Hematol, 92(1): E11–E13. https://doi.org/10.1002/ajh.24594
Zah E, Lin MY, Silva-Benedict A, et al., 2016. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res, 4(6):498–508. https://doi.org/10.1158/2326-6066.CIR-15-0231
Zanetti SR, Romecin PA, Vinyoles M, et al., 2020. Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity. J Immunother Cancer, 8(2): e001419. https://doi.org/10.1136/jitc-2020-001419
Zebley CC, Brown C, Mi T, et al., 2021. CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia. Cell Rep, 37(9):110079. https://doi.org/10.1016/j.celrep.2021.110079
Zhang L, Tian L, Dai XY, et al., 2020. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J Hematol Oncol, 13:153. https://doi.org/10.1186/s13045-020-00983-2
Zhang Z, Chen XF, Tian YG, et al., 2020. Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy. J Immunother Cancer, 8(2):e001150. https://doi.org/10.1136/jitc-2020-001150
Zheng WC, Xue QF, Sha XP, et al., 2021. Successful PD-1 inhibitor treatment in a patient with refractory transformed follicular lymphoma who failed to respond to CAR-T cell therapy: a case report and literature review. Cancer Biol Ther, 22(10–12):537–543. https://doi.org/10.1080/15384047.2021.1967083
Zhou Z, Han Y, Pan HB, et al., 2021. Tri-specific CD19×CD20×CD22 VHH CAR-T cells (LCAR-AIO) eradicate antigen-heterogeneous B cell tumors, enhance expansion, and prolong persistence in preclinical in vivo models. Blood, 138(S1):1700. https://doi.org/10.1182/blood-2021-150650
Zhou ZL, van der Jeught K, Fang YZ, et al., 2021. An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity. Nat Biomed Eng, 5(11):1320–1335. https://doi.org/10.1038/s41551-021-00805-x
Acknowledgments
This work was supported by the National Natural Science Foundation of China (No. 81730008).
Author information
Authors and Affiliations
Contributions
Tianning GU and Meng ZHU wrote the original manuscript. Tianning GU drafted the figures. Yongxian HU and He HUANG were responsible for conceptualization and manuscript revision. All authors have read and approved the final manuscript, and therefore, have full access to all the data in the study and take responsibility for the integrity and security of the data.
Corresponding authors
Additional information
Compliance with ethics guidelines
Tianning GU, Meng ZHU, He HUANG, and Yongxian HU declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this review.
This review does not contain any studies with human or animal subjects performed by any of the authors.
Rights and permissions
About this article
Cite this article
Gu, T., Zhu, M., Huang, H. et al. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches. J. Zhejiang Univ. Sci. B 23, 793–811 (2022). https://doi.org/10.1631/jzus.B2200256
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.B2200256